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Unopposed oestrogen replacement therapy (ORT) is an established
risk factor for endometrial adenocarcinoma (Grady et al, 1995).
The relation between hormone replacement therapy (HRT) and
ovarian cancer remains uncertain, however. Since cancer of the
ovary shares some risk factors with cancer of the endometrium,
such as low parity (Whittemore et al, 1992) and obesity (Purdie et
al, 1995), post-menopausal oestrogen therapy may also have a role
in its aetiology. This may particularly be so for the endometrioid
epithelial form, which is histologically similar to adenocarcinoma
of the endometrium (Russel, 1994). Some studies have shown
unopposed oestrogen therapy for at least 1 year to be associated
with an increase in risk of endometrioid tumours predominantly
(La Vecchia et al, 1982; Weiss et al, 1982; Cramer et al, 1983;
Risch, 1996) while others have suggested either no effect (Booth
et al, 1989; Kaufman et al, 1989; Whittemore et al, 1992) or an
inverse association (Hartge et al, 1988; Hempling et al, 1997)
between oestrogens and this type of ovarian cancer. Some of these
studies, however, have involved small numbers of exposed cases
(La Vecchia et al, 1982; Cramer et al, 1983; Kaufman et al, 1989),
have not distinguished unopposed oestrogen from oestrogen given
in combination with progestogen (Booth et al, 1989; Hempling et
al, 1997), or have used hospital controls (Hartge et al, 1988; Booth
et al, 1989; Kaufman et al, 1989; Hempling et al, 1997) with
possible overestimation of general exposure rates (Rodriguez et al,
1995). Hence, the issue is currently unresolved.
We report here the results of a large Australian case–control
study in which the relation between HRT, and in particular unop-
posed ORT, and epithelial ovarian cancer, both overall and among
histological types, was explored. We also examined any potential
modification of the effect of ORT on ovarian cancer risk by tubal
sterilization and hysterectomy.
METHODS
Histologically confirmed incident cases of primary epithelial
ovarian cancer registered in major gynaecological-oncology treat-
ment centres in three Australian states were ascertained. Cases
diagnosed in 1991 and 1992 in New South Wales and Victoria,
and from August 1990 to the end of 1993 in Queensland were
recruited. The histological types of all cancers of women included
in the study were reviewed by an independent gynaecological
pathologist in each state, as described in detail elsewhere (Purdie
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overall and risk of ovarian cancer. Unopposed oestrogen replacement therapy was, however, associated with a significant increase in risk of
endometrioid or clear cell epithelial ovarian tumours (odds ratio (OR) 2.56; 95% confidence interval (CI) 1.32–4.94). In addition, the risk
associated with oestrogen replacement therapy was much larger in women with an intact genital tract (OR 3.00; 95% Cl 1.54–5.85) than in
those with a history of either hysterectomy or tubal ligation. Post-menopausal oestrogen replacement therapy may, therefore, be a risk factor
associated with endometrioid and clear cell tumours in particular. Additionally, the risk may be increased predominantly in women with an
intact genital tract. These associations could reflect a possible role of endometriosis in the development of endometrioid or clear cell ovarian
tumours. © 1999 Cancer Research Campaign
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Hospital, Ipswich Road, Woolloongabba, Queensland 4102, Australiaet al, 1995). Briefly, ovarian cancer patients aged 18–79 years at
diagnosis who were capable of completing the questionnaire were
eligible to participate. A control series was selected at random
from the electoral roll (enrolment to vote is compulsory in
Australia) frequency matched to cases on age (20-year bands) and
broad geographic region. Women with a history of ovarian cancer
or bilateral oophorectomy, were not eligible to be controls; cases
not on the electoral roll were excluded from the analysis.
Identically trained interviewers administered a standard ques-
tionnaire to each woman in a face-to-face interview to obtain
personal details including education, height and weight, smoking
history, family history of ovarian and other cancers, full reproduc-
tive and contraceptive histories and age at menopause. Questions
were also asked about tubal sterilization and hysterectomy, and
with the women’s written consent, confirmation of these pro-
cedures was sought from relevant medical practitioners as
described previously (Green et al, 1997a).
Information was gathered about use of HRT, specifically the
type of hormones, doses, age at first use and duration of use were
recorded for up to three different types of treatment. Any HRT
used by cases after diagnosis was not considered; and those using
HRT at diagnosis were considered to be current users. HRT use in
controls was treated similarly.
Relative risks of ovarian cancer, both overall and within subcat-
egories, were estimated using multiple logistic regression to
simultaneously adjust for age (in years), level of education,
residential location, parity, duration of oral contraceptive pill use,
talc use in the perineal region, body mass index (BMI), smoking
status, hysterectomy and tubal sterilization (where appropriate)
and a family history of breast or ovarian cancer (Purdie et al,
1995). Women who had ever used unopposed ORT for at least
1 month were compared with those who had never used HRT, so
women who had used other forms of HRT (63 cases and 74
controls) were excluded from the unopposed oestrogen analyses.
Similar analyses were performed among women with and without
a history of tubal sterilization or hysterectomy to assess potential
effect modification from these procedures. Interactions between
factors were assessed using the product term in the logistic
regression models. All analyses were carried out using the SAS
statistical package.
RESULTS
There were 793 eligible cases and 855 eligible controls in the
study representing response rates of 90% and 73% respectively.
Ovarian cancer was subdivided into five histological groups:
serous (415, 52%); endometrioid and the related clear cell (164,
21%); mucinous (114, 14%); poorly differentiated adenocarci-
nomas (54, 7%); and mixed epithelial tumours with malignant
mixed mesodermal/Müllerian tumours (44, 6%). Two cases with
transitional cell (malignant Brenner) tumours were not included in
the subtype analyses.
Overall, 131 cases (16.5%) and 149 controls (17.4%) reported
ever taking any form of HRT for menopause-related reasons,
which is consistent with cross-sectional data from a similar aged
population-based Australian study (Dennerstein et al, 1994). Of
these, 68 cases (8.6%) and 75 controls (8.8%) reported ever using
unopposed ORT. After adjustment for potential confounders, there
were no significant associations found between occurrence of
ovarian cancer and ever use of HRT, either overall or in its various
forms (Table 1). There were also no clear trends in risk for
increased duration of HRT use or time since last use, either overall
or for the most common forms (Table 2).
There was, however, higher use of ORT among cases with
endometrioid or clear cell cancers than among controls or other
cases and, after adjustment for potential confounders, a marked
and significant elevation in risk among this group of cases was
observed (Table 3). A comparison of the effect in endometrioid or
clear cell tumours with the effect in other tumour types approached
significance (P = 0.06). The separate risks for endometrioid and
for clear cell tumours were nearly identical.
Women who reported having either a hysterectomy or tubal
sterilization had higher usage of HRT, in particular unopposed
oestrogen: 30% of women with a hysterectomy and 15% of women
with a tubal sterilization had ever used ORT, compared with only
6% of women without such surgery. These women were also at
lower risk of ovarian cancer (Green et al, 1997b). We therefore
examined whether hysterectomy or tubal sterilization, as well as
being confounders, modified the relationship between ever use of
ORT and ovarian cancer risk. For all cases, an inverse association
between unopposed oestrogen use and ovarian cancer was seen in
women with a prior hysterectomy, and no relationship was seen in
those with tubal sterilization alone. In contrast, women who
reported neither hysterectomy nor tubal sterilization exhibited a
moderately strong and significant increase in risk associated with
ORT (Table 4). The interaction effects between hysterectomy and
ORT and between tubal sterilization and ORT among those women
without a hysterectomy were significant (P = 0.006 and 0.04
respectively). Relative risks of unopposed oestrogen therapy were
also higher for endometrioid and clear cell tumours than for other
tumours among women with a prior hysterectomy or tubal steriliza-
tion and strikingly so among those without surgery (Table 4).
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Table 1 Ever use of hormone replacement therapy among all cases of epithelial ovarian cancer and controls with crude and adjusted odds ratios
HRT use Cases Controls Crude OR Adjusted ORb
(n = 793)a (n = 855)a (95% CI) (95% CI)
Nonec 83.5% 82.6% 1.00 1.00
Any HRT 16.5% 17.4% 0.94 (0.72–1.21) 1.20 (0.90–1.60)
Unopposed oestrogen 8.6% 8.8% 0.97 (0.68–1.36) 1.27 (0.86–1.88)
Unopposed progestogen 1.8% 1.3% 1.36 (0.61–3.01) 2.18 (0.91–5.20)
Oestrogen and progestogen in combination 4.9% 5.4% 0.90 (0.58–1.40) 1.34 (0.83–2.17)
Not known 2.9% 2.7% 1.07 (0.59–1.92) 1.05 (0.55–2.01)
aThe combined total number from treatment groups is greater than the total number of HRT users as 13 cases and six controls reported use of different
hormone treatments at different times. bORs adjusted for age, education, area of residence, BMI, hysterectomy, tubal sterilization, talc use in perineal region,
smoking status, duration of OCP use, parity and a family history of breast or ovarian cancer. cReference category for all forms of HRT.The effect of ORT was essentially uniform across the different
levels of duration of use, irrespective of surgical history or histo-
logical type of tumour. There was, however, a distinct decrease in
risk of ovarian cancer seen with increasing time since last use
among women with an intact reproductive system. In this group,
compared with never-users of HRT, current ORT users were at
highest risk (OR 3.92; 95% CI 1.32–11.6); women who had ceased
use within the last 5 years were at intermediate risk (OR 2.09; 95%
CI 0.90–4.89); and women who had last used oestrogen more than
5 years ago were at lowest risk (OR 1.45; 95% CI 0.90–2.32). No
similar trend in risk with time since last use of ORT was apparent
in those with a previous hysterectomy or tubal sterilization.
Oestrogen doses were too poorly reported by subjects for a useful
analysis.
No associations similar to those seen with unopposed oestrogen
were found for any other form of HRT.
DISCUSSION
A non-significant 20% increase in risk of ovarian cancer was found
to be associated with ever use of HRT, which is consistent with
summary estimates reported in a recently published meta-analysis
on the subject (Garg et al, 1998). Ovarian carcinomas are, however,
a heterogeneous collection, morphologically, pathogenically and
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Table 2 Duration of use and time since last use of hormone replacement therapy, overall and specifically for unopposed oestrogen and oestrogen in
combination with progestogen, among all cases of epithelial ovarian cancer and controls with crude and adjusted odds ratios
HRT use Cases Controls Crude OR Adjusted ORa
(n = 793) (n = 855) (95% CI) (95% CI)
Never usedb 83.5% 82.6% 1.00 1.00
Used any HRT forc
<1 year 3.5% 5.1% 0.68 (0.42–1.10) 0.70 (0.41–1.19)
1–3 years 5.3% 4.9% 1.07 (0.69–1.66) 1.11 (0.88–1.41)
>3 years 6.3% 6.3% 0.99 (0.66–1.47) 1.13 (0.91–1.41)
Last used any HRT
Current users 8.6% 11.0% 0.77 (0.55–1.07) 0.95 (0.67–1.36)
1–5 years ago 3.5% 2.7% 1.30 (0.74–2.28) 1.28 (0.95–1.72)
>5 years ago 3.0% 2.7% 1.11 (0.62–1.99) 1.03 (0.75–1.42)
Used unopposed oestrogen for
< 1 year 2.4% 2.6% 0.92 (0.49–1.72) 0.93 (0.47–1.85)
1–3 years 3.4% 3.0% 1.11 (0.64–1.92) 1.13 (0.85–1.50)
>3 years 2.7% 3.2% 0.83 (0.46–1.48) 0.92 (0.67–1.25)
Last used unopposed oestrogen
Current users 3.5% 4.3% 0.81 (0.49–1.33) 0.94 (0.56–1.60)
1–5 years ago 2.3% 1.8% 1.28 (0.64–2.56) 1.19 (0.82–1.72)
>5 years ago 2.6% 2.7% 0.97 (0.53–1.78) 0.94 (0.67–1.30)
Used oestrogen and progestogen in combination for
<1 year 1.1% 1.6% 0.69 (0.29–1.59) 0.80 (0.33–1.97)
1–3 years 1.9% 1.6% 1.14 (0.55–2.39) 1.36 (0.92–2.00)
>3 years 1.8% 1.6% 1.07 (0.50–2.25) 1.33 (0.88–2.00)
Last used oestrogen and progestogen in combination
Current users 3.9% 4.6% 0.85 (0.52–1.37) 1.24 (0.73–2.09)
Past users 0.9% 0.4% 2.49 (0.64–9.66) 2.02 (0.99–4.14)
aORs adjusted for age, education, area of residence, BMI, hysterectomy, tubal sterilization, talc use in perineal region, smoking status, duration of OCP use,
parity and a family history of breast or ovarian cancer. bReference category for all forms of HRT. cEleven cases and nine controls did not report on duration of
HRT use (and hence time since last use could also not be calculated).
Table 3 Ever use of unopposed oestrogen replacement therapy among women with various histological types of ovarian cancer and among controls
Histological type ORT users Never used Crude OR Adjusted ORb
HRTa (95% Cl) (95% CI)
Controls 75 (8.8%)c 706 (82.6%) 1.00 1.00
All cancers 68 (8.6%) 662 (83.5%) 0.97 (0.69–1.36) 1.27 (0.86–1.88)
Serous 36 (8.7%) 340 (81.9%) 1.00 (0.66–1.51) 1.26 (0.78–2.03)
Endometrioid/clear cell 18 (11.0%) 132 (80.5%) 1.28 (0.74–2.22) 2.56 (1.32–4.94)
Mucinous 6 (5.3%) 106 (93.0%) 0.53 (0.23–1.25) 0.85 (0.32–2.23)
Undifferentiated 4 (7.4%) 45 (83.3%) 0.84 (0.29–2.39) 0.51 (0.14–1.89)
Mixed epithelial/mesodermal 4 (9.1%) 38 (86.4%) 0.99 (0.34–2.85) 1.15 (0.35–3.80)
aExcludes women who used another form of HRT (63 cases, 74 controls). bORs adjusted for age, education, area of residence, BMI, hysterectomy, tubal
sterilization, talc use in perineal region, smoking status, duration of OCP use, parity and a family history of breast or ovarian cancer. cPercentages are based on
row totals (including users of other forms of HRT).aetiologically (Russell, 1994). Many epidemiological studies have
assumed homogeneity for the purposes of studying general aetio-
logical factors. An important outcome has been revealed in the
histological subtype analysis of this case–control study, namely, the
moderately strong association found between ever use of unop-
posed oestrogen and endometrioid or, the closely related, clear cell
tumours. This parallels the findings of a number of certain other
studies that looked specifically at endometrioid ovarian cancers (La
Vecchia et al, 1982; Weiss et al, 1982; Cramer et al, 1983; Risch,
1996), although not all (Hartge et al, 1988; Booth et al, 1989;
Kaufman et al, 1989; Whittemore et al, 1992; Hempling et al,
1997). Endometrioid and clear cell tumours are broadly regarded as
the equivalent of the same cancers in the endometrium (showing
proliferative, or ‘pregnancy-related’ secretory changes), whereas
serous tumours are neoplastic analogues of the fallopian tube
mucosa and mucinous tumours are similar to those of the endo-
cervix or colon (Scully, 1977). An analogy can therefore be drawn
between our findings and those in endometrial cancer in which the
relationship with oestrogens is most marked for the endometrioid
and least strong for serous papillary carcinomas (Bokham, 1983;
Smith and McCartney, 1985).
It is clear that the aetiology of endometrial adenocarcinomas is
linked to the role of oestrogens (IARC, 1987). That endometrial
adenocarcinoma is a ‘generic diagnosis’ and represents a heteroge-
neous group of neoplasms is also clear, as it is for ovarian cancers
(Greven and Corn, 1997).
A finding of interest was that unopposed ORT was inversely
associated with all ovarian cancers in women with a prior
hysterectomy (although not significantly), but positively associ-
ated in women without either hysterectomy or tubal sterilization.
In women with tubal sterilization no association was observed.
While this is not the first study to report a lower risk of ovarian
cancer associated with ORT among women with a hysterectomy
(Whittemore et al, 1992; Hartge et al, 1988), others have reported
a larger effect of ORT in this group (Booth et al, 1989; Kaufman et
al, 1989) or no difference (Risch, 1996). However, no previous
study has examined the effect of ORT stratified by hysterectomy
and tubal sterilization. The association seen here may imply that
non-contraceptive-oestrogen is a risk factor specifically for
women with an intact genital tract. In all categories of surgical
history, the endometrioid/clear cell group of tumours retained their
elevated risk relative to other tumour types. In addition, among
women with an intact genital tract, there was also a noticeable
decrease in risk with increasing time since last use of unopposed
oestrogen, consistent with the type of association with endometrial
carcinomas found by some (Green et al, 1996), though not all
studies (Paganini-Hill et al, 1989).
The positive links seen with ORT may reflect the suggested role
of ovarian endometriosis in the aetiology of endometrioid or clear
cell ovarian cancer (Sainz de la Cuesta et al, 1996). Post-
menopausal ORT could cause proliferation of the uterine
endometrium, and in women with an intact genital tract, could
therefore increase the risk of retrograde menstruation (Metzger
and Haney, 1989). This, in combination with the increased levels
of circulating oestrogens from the oestrogen therapy, could
promote ovarian endometriosis (Faulkner and Riemenschneider,
1945). Women without hysterectomy or tubal sterilization who are
prescribed unopposed oestrogen may therefore have an increased
risk of subsequent ovarian endometriosis and consequently have a
higher risk of endometrioid or clear cell ovarian cancer (Sainz de
la Cuesta et al, 1996; Paulson, 1997).
Contrary to what might be expected given the well-established
association between oestrogen and endometrial adenocarcinoma,
unopposed oestrogen was prescribed for some women with an
intact uterus in our study until quite recently. Year of first use is,
therefore, unlikely to be a major confounding factor. Further,
among the 73 women who both used unopposed oestrogen and
had a hysterectomy, only three began use of oestrogen before the
operation and all three continued use after surgery.
We do not believe that selection or recall biases could have
accounted for our finding (Purdie et al, 1995). It is unlikely the
results could be explained by incorrect reporting of operations
since self-reported histories of hysterectomy and tubal sterilization
were checked against available medical reports and 96% and 88%
respectively were confirmed (Green et al, 1997a). Furthermore,
recall of unopposed ORT would hardly differ from other forms of
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Table 4 Ever use of unopposed oestrogen replacement therapy in women with and without hysterectomy and tubal sterilization
Subgroup of women ORT users Never used Crude OR Adjusted ORb
HRTa (95% CI) (95% CI)
With hysterectomy:
Controls 51 (29.8%)c 114 (66.7%) 1.00 1.00
All cases 22 (19.5%) 80 (70.8%) 0.61 (0.35–1.09) 0.65 (0.34–1.24)
Endometrioid/clear cell 5 (33.3%) 9 (60.0%) 1.24 (0.40–3.89) 1.75 (0.43–7.14)
Other cases 17 (17.4%) 71 (72.4%) 0.53 (0.29–1.00) 0.57 (0.29–1.15)
Without hysterectomy but with tubal sterilization:
Controls 9 (5.8%) 123 (79.3%) 1.00 1.00
All cases 5 (5.7%) 74 (84.1%) 0.92 (0.30–2.86) 1.03 (0.27–3.96)
Endometrioid/clear cell 2 (12.5%) 13 (81.3%) 2.10 (0.41–10.8) 2.72 (0.27–27.3)
Other cases 3 (4.2%) 61 (84.7%) 0.67 (0.18–2.57) 0.84 (0.17–4.12)
Without hysterectomy or tubal sterilization:
Controls 15 (2.8%) 469 (88.7%) 1.00 1.00
All cases 41 (6.9%) 508 (85.8%) 2.52 (1.38–4.62) 3.00 (1.54–5.85)
Endometrioid/clear cell 11 (8.3%) 110 (82.7%) 3.13 (1.40–7.00) 4.29 (1.67–11.1)
Other cases 30 (6.5%) 398 (86.7%) 2.36 (1.25–4.44) 2.66 (1.31–5.37)
aExcludes women who used another form of HRT (63 cases, 74 controls). bORs adjusted for age, education, area of residence, BMI, talc use in perineal region,
smoking status, duration of OCP use, parity and a family history of breast or ovarian cancer. cPercentages are based on row totals (including users of other
forms of HRT).HRT, which did not show similar effects. However, many of the
associations observed in this investigation of HRT were based on
small numbers: only 18 cases of endometrioid or clear cell ovarian
cancer had ever used unopposed ORT. When further subdivided by
history of gynaecological surgery, this problem was even more
pronounced.
Prior efforts to evaluate the effects of menopausal oestrogenic
agents on ovarian carcinomas as a whole have been inconsistent,
some studies showing an increase in risk (Weiss et al, 1982) some
a decrease (Hartge et al, 1988; Hempling et al, 1997) and others no
significant effect (La Vecchia et al, 1982; Kaufman et al, 1989;
Purdie et al, 1995). These inconsistencies may be due to the histo-
logical type-specific associations observed in these data, as well
as to the effect modification observed with certain genital tract
surgery. Those studies that examined the effect of menopausal
oestrogen separately for the different types of ovarian cancer have
also yielded contradictory findings. Those not finding a positive
association more often used hospital based controls (Hartge et al,
1988; Booth et al, 1989; Kaufman et al, 1989; Hempling et al,
1997), which may reflect an excess of HRT use among hospital-
ized women (Rodriguez et al, 1995).
In conclusion, our results are consistent with the possibility that
some utero-ovarian carcinogenic influence, such as endometriosis,
is promoted by ORT, increasing the risk of endometrioid and clear
cell ovarian carcinomas.
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